These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 8398322)

  • 1. The real costs of emesis--an economic analysis of ondansetron vs. metoclopramide in controlling emesis in patients receiving chemotherapy for cancer.
    Cunningham D; Gore M; Davidson N; Miocevich M; Manchanda M; Wells N
    Eur J Cancer; 1993; 29A(3):303-6. PubMed ID: 8398322
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ondansetron: a cost-effective advance in anti-emetic therapy.
    Cox F; Hirsch J
    Oncology; 1993; 50(3):186-90. PubMed ID: 8459990
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ondansetron: a pharmacoeconomic and quality-of-life evaluation of its antiemetic activity in patients receiving cancer chemotherapy.
    Plosker GL; Milne RJ
    Pharmacoeconomics; 1992 Oct; 2(4):285-304. PubMed ID: 10147044
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cost-effectiveness analysis of antiemetic therapy for ambulatory surgery.
    Watcha MF; Smith I
    J Clin Anesth; 1994; 6(5):370-7. PubMed ID: 7986508
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cost and cost-effectiveness analysis of ondansetron versus metoclopramide regimens: a hospital perspective from Italy.
    Ballatori E; Roila F; Berto P; De Angelis V; Neri C; Olivieri A; Tonato M; Del Favero A
    Pharmacoeconomics; 1994 Mar; 5(3):227-37. PubMed ID: 10146897
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of ondansetron with metoclopramide in prevention of acute emesis associated with low dose & high dose cisplatin chemotherapy.
    Bhatia A; Tripathi KD; Sharma M
    Indian J Med Res; 2003 Jul; 118():33-41. PubMed ID: 14748464
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cost-effectiveness and quality of life evaluation of ondansetron and metoclopramide for moderately emetogenic chemotherapy regimens in breast cancer.
    Lachaine J; Laurier C; Langleben A; Vaillant L
    Crit Rev Oncol Hematol; 1999 Nov; 32(2):105-12. PubMed ID: 10612010
    [No Abstract]   [Full Text] [Related]  

  • 8. Pharmacoeconomic analysis of ondansetron versus metoclopramide for cisplatin-induced nausea and vomiting.
    Zbrozek AS; Cantor SB; Cardenas MP; Hill DP
    Am J Hosp Pharm; 1994 Jun; 51(12):1555-63. PubMed ID: 8092156
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Economic evaluation of ondansetron: preliminary analysis using clinical trial data prior to price setting.
    Buxton MJ; O'Brien BJ
    Br J Cancer Suppl; 1992 Dec; 19():S64-7. PubMed ID: 1467204
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Costs of treating and preventing nausea and vomiting in patients receiving chemotherapy.
    Stewart DJ; Dahrouge S; Coyle D; Evans WK
    J Clin Oncol; 1999 Jan; 17(1):344-51. PubMed ID: 10458253
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy & tolerability of ondansetron compared to metoclopramide in dose dependent cisplatin-induced delayed emesis.
    Bhatia A; Tripathi KD; Sharma M
    Indian J Med Res; 2004 Sep; 120(3):183-93. PubMed ID: 15489556
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A single-blind comparison of intravenous ondansetron, a selective serotonin antagonist, with intravenous metoclopramide in the prevention of nausea and vomiting associated with high-dose cisplatin chemotherapy.
    Hainsworth J; Harvey W; Pendergrass K; Kasimis B; Oblon D; Monaghan G; Gandara D; Hesketh P; Khojasteh A; Harker G
    J Clin Oncol; 1991 May; 9(5):721-8. PubMed ID: 1826739
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of ondansetron-dexamethasone-lorazepam versus metoclopramide-dexamethasone-lorazepam in the control of cisplatin induced emesis.
    Manusirivithaya S; Chareoniam V; Isariyodom P; Sungsab D
    J Med Assoc Thai; 2001 Jul; 84(7):966-72. PubMed ID: 11759977
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ondansetron versus metoclopramide, both combined with dexamethasone, in the prevention of cisplatin-induced delayed emesis. The Italian Group for Antiemetic Research.
    J Clin Oncol; 1997 Jan; 15(1):124-30. PubMed ID: 8996133
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Recent improvements in antiemetic therapy].
    Roila F; Palladino MA; Ciccarese G; Basurto C
    Tumori; 1997; 83(2 Suppl):S3-14. PubMed ID: 9235727
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A randomised, double-blind, parallel-group study to compare the efficacy and safety of ondansetron (GR38032F) plus dexamethasone with metoclopramide plus dexamethasone in the prophylaxis of nausea and emesis induced by carboplatin chemotherapy.
    du Bois A; McKenna CJ; Andersson H; Lahousen M; Kitchener H; Pinter T; Capstick V; Wilkinson JR
    Oncology; 1997; 54(1):7-14. PubMed ID: 8978585
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A randomized double-blind comparison of ondansetron and metoclopramide in the prophylaxis of emesis induced by cyclophosphamide, fluorouracil, and doxorubicin or epirubicin chemotherapy.
    Bonneterre J; Chevallier B; Metz R; Fargeot P; Pujade-Lauraine E; Spielmann M; Tubiana-Hulin M; Paes D; Bons J
    J Clin Oncol; 1990 Jun; 8(6):1063-9. PubMed ID: 2140854
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Randomised comparison of ondansetron and metoclopramide plus dexamethasone for chemotherapy induced emesis.
    Dick GS; Meller ST; Pinkerton CR
    Arch Dis Child; 1995 Sep; 73(3):243-5. PubMed ID: 7492164
    [TBL] [Abstract][Full Text] [Related]  

  • 19. High efficacy of a single oral dose of ondansetron 8 mg versus a metoclopramide regimen in the prevention of acute emesis induced by fluorouracil, doxorubicin and cyclophosphamide (FAC) chemotherapy for breast cancer.
    Bosnjak SM; Nesković-Konstantinović ZB; Radulović SS; Susnjar S; Mitrovi LB
    J Chemother; 2000 Oct; 12(5):446-53. PubMed ID: 11128567
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ondansetron plus dexamethasone compared to the 'standard' metoclopramide combination.
    Roila F
    Oncology; 1993; 50(3):163-7. PubMed ID: 8459986
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.